Article

iScience receives clearance for use of microcatheters for POAG

Menlo Park, CA-iScience Interventional has received expanded 510(k) clearance from the FDA to allow ophthalmic surgeons to use its microcatheters to enlarge outflow passages to reduce IOP in the treatment of primary open-angle glaucoma (POAG).

Menlo Park, CA-iScience Interventional has received expanded 510(k) clearance from the FDA to allow ophthalmic surgeons to use its microcatheters to enlarge outflow passages to reduce IOP in the treatment of primary open-angle glaucoma (POAG). Canaloplasty has been performed worldwide for more than 3 years.

“Canaloplasty strengthens the ophthalmologists’ options for patients with POAG,” said Richard A. Lewis, MD, in private practice in Sacramento, CA. “Ophthalmologists have recognized for decades that the ideal solution to glaucoma would restore or maintain the eye’s natural drainage system. The canaloplasty does just that.”

Bradford J. Shingleton, MD, associate clinical professor of ophthalmology, Harvard Medical School, Boston, added, “The canaloplasty is a procedure that is grounded in high technology and science. Over the past several years, respected researchers in Europe, Canada, and the United States have amassed clinical data that support the safety and efficacy of canaloplasty for patients with POAG as well as the significant reduction of costly medications.”

Michael Nash, president of iScience Interventional, said, “Microcatheters represent an exciting new frontier for ophthalmology. We believe that interventional procedures will significantly alter the treatment paradigm for a wide range of eye diseases and disorders in the future.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.